Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Nanfang Medical CoSHSE:603880 +0.47%50 EBITDA Margin % is 0.36% as of Mar. 2026, which is 95% below its 10-year median of 7.80. GuruFocus rates SHSE:603880 with a GF Score™ of 50/100 and a GF Value™ of ¥4.71 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Jiangsu Nanfang Medical Co ranks worse than 68.83% on this metric.
Jiangsu Nanfang Medical Co (SHSE:603880) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Nanfang Medical Co EBITDA Margin % Related Terms
Jiangsu Nanfang Medical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603880 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Jiangsu Nanfang Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Nanfang Medical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jiangsu Nanfang Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Nanfang Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Nanfang Medical Co (SHSE:603880) has a EBITDA Margin % of 0.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Nanfang Medical Co and its competitors. This is 95% below median its historical median of 7.80. According to the industry distribution chart, Jiangsu Nanfang Medical Co ranks #561 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 68.8%.
Is Jiangsu Nanfang Medical Co's EBITDA Margin % too high?
Jiangsu Nanfang Medical Co's current EBITDA Margin % of 0.36% is 95% below median its 10-year median of 7.80. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Jiangsu Nanfang Medical Co's value of 0.36% is 95.2% below this industry median. Based on the distribution chart, Jiangsu Nanfang Medical Co ranks #561 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Jiangsu Nanfang Medical Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Nanfang Medical Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Jiangsu Nanfang Medical Co ranks #561 out of 815 companies for EBITDA Margin %. This places Jiangsu Nanfang Medical Co in the lower half of its industry. The industry median EBITDA Margin % is 7.52. Jiangsu Nanfang Medical Co's value of 0.36% is 95.2% below this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 7.52, Jiangsu Nanfang Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Nanfang Medical Co's current EBITDA Margin % of 0.36% is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Nanfang Medical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Nanfang Medical Co's current EBITDA Margin % is 0.36%, which is 95% below median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Nanfang Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co (SHSE:603880) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.71, compared to a current price of ¥6.37 — trading 35.2% above its estimated fair value. The current EBITDA Margin % is 0.36%, which is 95% below median its 10-year median of 7.80 and 95.2% below the Medical Devices & Instruments industry median of 7.52. Jiangsu Nanfang Medical Co's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Nanfang Medical Co (SHSE:603880), the current EBITDA Margin % is 0.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Nanfang Medical Co (SHSE:603880) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co stock appears to be overvalued.
The current stock price of ¥6.37 is trading 35.2% above its estimated GF Value™ of ¥4.71.
GuruFocus considers Jiangsu Nanfang Medical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603880:
EBITDA Margin %: 0.36% (95% below median its 10-year median of 7.80)
GF Value™: ¥4.71 vs. price of ¥6.37 (35.2% above fair value)
Industry Position: 95.2% below the Medical Devices & Instruments median (#561 of 815)
No single metric tells the full story. See the SHSE:603880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Nanfang Medical Co Ltd is a domestic adhesive dressing production enterprise that integrates research and development, production, and sales. It produces a band-aid in China. The company is focused on the development of self-owned brand products such as first-aid kits, sports protection products, and care products on the basis of the original series of Miaoshou medical dressings.
50GF Score
Get the complete analysis for SHSE:603880
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603880 has been successfully added to your 
